COL9A2

Across TCGA pan-cancer cohorts, COL9A2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated COL9A2 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher COL9A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated COL9A2 expression acts as an unfavorable survival marker.

ESCA, HNSC, and UCEC are the cancer types where COL9A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.094	0.536	<.001	18	view →
HNSC	DFS	Median	All	0.078	0.710	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.094	0.429	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

COL9A2–ESCA (DFS)

Open the ESCA breakdown →